Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS9531 injection, which will conduct clinical trials in the near future.

HRS9531 injection is a novel dual agonist targeting gastric suppressive peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) with HRS9531 as the main active ingredient. Its marketing application for long-term adult weight management was accepted by the State Drug Administration in September 2025.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.